TITLE

BRAND-NAME PRESCRIPTION DRUG PRICING: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases

PUB. DATE
January 2010
SOURCE
GAO Reports;1/11/2010, preceding p1
SOURCE TYPE
Government Document
DOC. TYPE
Article
ABSTRACT
The article highlights the study of Government Accountability Office (GAO) which examines the growing cost of brand-name prescription drugs with extraordinary price increase in the U.S. It notes that Food and Drug Administration-approved drug products that have patent protection concern the patients, payers and providers of health care when the prices increase suddenly in large amount. In this regard, GAO examines the extraordinary price increase for the brand-name price increase.
ACCESSION #
47731686

 

Related Articles

  • CAPITOL HEALTH CALL. Mitka, Mike // JAMA: Journal of the American Medical Association;12/9/2009, Vol. 302 Issue 22, p2423 

    This section presents an update on issues related to medical care in the U.S. The Government Accountability Office (GAO) reported that the marketing oversight of the Food and Drug Administration (FDA) for drugs remained poor from 1998 to 2008. Democratic Representative Michael Honda of...

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • FDA Questioned by Other Feds on High-Risk Devices. Reed, Vita // Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65 

    The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient...

  • GAO: Launch of ObamaCare insurance exchanges in doubt. Viebeck, Elise // Hill;6/20/2013, Vol. 20 Issue 75, p11 

    The article focuses on a report from the U.S. Government Accountability Office (GAO) regarding the launch of healthcare law by President Barack Obama which might not be ready for prime time when people signed up for the new insurance exchanges on October 1, 2013.

  • FDA moves to streamline patient info. Dickinson, James G. // Medical Marketing & Media;Dec2012, Vol. 47 Issue 12, p34 

    The article reports on the efforts of the drugs center of the U.S. Food and Drug Administration (FDA) to draft a regulation in order to implement the proposed Patient Medication Information (PMI) sheet in the near future.

  • FDA final guidance on 'Dear Healthcare Provider' letters.  // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p6 

    The article reports that a guidance document titled "Dear Health Care Provider Letters: Improving Communication of Important Safety Information," has been released by the Food & Drug Administration (FDA). It offers information on the content and format of Dear Healthcare Provider (DHCP) letters...

  • Hamburg Describes Efforts to Develop Medical Countermeasures. Drakulich, Angie // Pharmaceutical Technology;Apr2011, Vol. 35 Issue 4, p26 

    The article reports on the potential contribution of Food and Drug Administration (FDA) to the medical countermeasures for responding to natural and deliberate threats to public health in the U.S. in 2011. It mentions the actions to be carried out by the agency which include its cooperation with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics